Filtered By:
Condition: Arthritis
Vaccination: Varicella-Zoster Virus Vaccine
This page shows you your search results in order of date.
Order by Relevance | Date
Total 34 results found since Jan 2013.
Post-licensure safety study of new-onset immune-mediated diseases, herpes zoster, and anaphylaxis in adult recipients of HepB-CpG vaccine versus HepB-alum vaccine
CONCLUSIONS: This large post-licensure study did not identify evidence of safety concerns for HepB-CpG compared to HepB-alum for immune-mediated diseases, HZ, or anaphylaxis.PMID:37308363 | DOI:10.1016/j.vaccine.2023.06.004
Source: Vaccine - June 12, 2023 Category: Allergy & Immunology Authors: Bradley Ackerson Lina S Sy Jeff Slezak Lei Qian Kristi Reynolds Runxin Huang Zendi Solano William Towner Sijia Qiu Sarah R Simmons Steven J Jacobsen Katia J Bruxvoort Source Type: research
Necrotizing pancreatitis, microangiopathic hemolytic anemia and thrombocytopenia following the second dose of Pfizer/BioNTech COVID-19 mRNA vaccine
We report a 31-year-old female with a history of borderline personality disorder, intravenous drug abuse, allergic asthma, eating disorder, psoriatic arthritis treated with tofacitinib, neurogenic bladder disturbance, cholecystectomy, recurrent thoracic herpes zoster, vaginal candida infections and urinary tract infections, who developed pancreatitis associated with thrombotic microangiopathy and hemolytic-uremic syndrome 10 days after the second vaccination, whereas the first has been well tolerated. She was treated by plasma exchange, and eventually by transgastric drainage with implantation of a plastic stent to remove ...
Source: Herpes - June 6, 2023 Category: Infectious Diseases Authors: Claudia St öllberger Kastriot Kastrati Clemens Dejaco Martina Scharitzer Josef Finsterer Patrick Bugingo Madeleine Melichart-Kotik Astrid Wilfing Source Type: research
Clinical and Economic Burden of Herpes Zoster in Patients with Rheumatoid Arthritis: A Retrospective Cohort Study Using Administrative Claims
CONCLUSIONS: These findings highlight the high economic burden of HZ among individuals with RA in the United States. Strategies to reduce the risk of HZ in patients with RA (such as vaccination) may serve to reduce this burden. Video abstract.PMID:37219822 | DOI:10.1007/s40744-023-00549-x
Source: Herpes - May 23, 2023 Category: Infectious Diseases Authors: David Singer Philippe Thompson-Leduc Sara Poston Deepshekhar Gupta Wendy Y Cheng Siyu Ma Francesca Devine Alexandra Enrique Mei Sheng Duh Jeffrey R Curtis Source Type: research
Engaging Multistakeholder Perspectives to Identify Patient-Centered Research Priorities Regarding Vaccine Uptake Among Adults With Autoimmune Conditions
CONCLUSION: A multistakeholder group identified key topics as critically important priorities for future research to decrease vaccine hesitancy and improve uptake of vaccines for adults with autoimmune conditions.PMID:37127530 | DOI:10.1002/acr2.11546
Source: Herpes - May 1, 2023 Category: Infectious Diseases Authors: Shilpa Venkatachalam Kelly Gavigan Laura Stradford Vandana Dronadula Angela Degrassi W Benjamin Nowell Shubhasree Banerjee Peter A Merkel Michael D George Jennifer Gordon Dianne G Shaw Kalen Larsen Lisa Emrich Robert N McBurney Hope Sullivan Ashira Blazer Source Type: research
Immunogenicity and Safety of Adjuvanted Recombinant Zoster Vaccine in Rheumatoid Arthritis Patients on Anti-Cellular Biologic Agents or JAK Inhibitors: A Prospective Observational Study
Int J Mol Sci. 2023 Apr 9;24(8):6967. doi: 10.3390/ijms24086967.ABSTRACTRheumatoid arthritis (RA) patients on JAK inhibitors (JAKi) have an increased HZ risk compared to those on biologic DMARDs (bDMARDs). Recently, the Adjuvanted Recombinant Zoster Vaccine (RZV) became available worldwide, showing good effectiveness in patients with inflammatory arthritis. Nevertheless, direct evidence of the immunogenicity of such a vaccine in those on JAKi or anti-cellular bDMARDs is still lacking. This prospective study aimed to assess RZV immunogenicity and safety in RA patients receiving JAKi or anti-cellular bDMARDs that are known t...
Source: Herpes - April 28, 2023 Category: Infectious Diseases Authors: Vincenzo Venerito Pasquale Stefanizzi Luca Cantarini Marlea Lavista Maria Grazia Galeone Antonio Di Lorenzo Florenzo Iannone Silvio Tafuri Giuseppe Lopalco Source Type: research
Conventional, biological disease-modifying anti-rheumatic drugs and Janus kinase inhibitors and varicella zoster virus
Expert Opin Pharmacother. 2023 Mar 22. doi: 10.1080/14656566.2023.2195050. Online ahead of print.ABSTRACTINTRODUCTION: The advent of biological disease-modifying anti-rheumatic drugs (bDMARDs), and more recently of Janus kinase inhibitors (JAKi), has had a major impact on the herpes zoster (HZ) reactivation, which represents an important clinical challenge in the treatment of inflammatory arthritis (IA) in patients with a complete pharmacological control of peripheral inflammation.AREAS COVERED: In this review, we provide an overview on the effects of conventional DMARDs/ bDMARDs and JAKi on HZ reactivation. Furthermore, w...
Source: Herpes - March 22, 2023 Category: Infectious Diseases Authors: Fabiola Atzeni Francesco Gozza Agostino Riva Alessandra Alciati James Galloway Source Type: research
Prevalence and risk factors of herpes zoster infection in patients with rheumatic diseases not receiving biologic or targeted therapies
CONCLUSIONS: Reactivation of HZ is fairly common in patients with rheumatic diseases. Underlying SLE, age, neutrophil/lymphocyte ratio, and immunosuppressive therapies are independent risk factors. Key Points • Herpes zoster (HZ) infection is fairly common in patients with rheumatic diseases undergoing conventional DMARD or immunosuppressive therapies. • Underlying SLE, increasing age, higher neutrophil/lymphocyte ratio and increasing dosages of immunosuppressive drugs are independent risk factors. • Patients with rheumatic diseases, particularly SLE, should be encouraged to receive HZ vaccination.PMID:36385600 | DOI...
Source: Herpes - November 17, 2022 Category: Infectious Diseases Authors: Chi Chiu Mok Ling Yin Ho Sau Mei Tse Kar Li Chan Chi Hung To Source Type: research
Comparative Safety of BNT162b2 and mRNA-1273 Vaccines in a Nationwide Cohort of US Veterans
CONCLUSIONS AND RELEVANCE: The findings of this cohort study suggest that there were few differences in risk of adverse events within 14 days of the first dose of either the BNT162b2 or the mRNA-1273 vaccine and small-magnitude differences within 42 days of the first dose. The 38-week risks of adverse events were low in both vaccine groups, although risks were lower for recipients of the mRNA-1273 vaccine than for recipients of the BNT162b2 vaccine. Although the primary analysis was designed to detect safety events unrelated to SARS-CoV-2 infection, the possibility that these differences may partially be explained by a low...
Source: Herpes - June 13, 2022 Category: Infectious Diseases Authors: Barbra A Dickerman Arin L Madenci Hanna Gerlovin Katherine E Kurgansky Jessica K Wise Michael J Figueroa Mu ñiz Brian R Ferolito David R Gagnon J Michael Gaziano Kelly Cho Juan P Casas Miguel A Hern án Source Type: research
